| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910460732903321 |
|
|
Titolo |
Down syndrome children-- and update / / edited by Mohammed Al-Biltagi, associate professor of pediatrics, Tanta University, Egypt |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Sharjah : , : Bentham Science Publishers, Limited, , [2015] |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (486 p.) |
|
|
|
|
|
|
Soggetti |
|
Down syndrome |
Child development |
Down syndrome - Patients |
Electronic books. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
|
|
|
|
|
Nota di contenuto |
|
CONTENTS; FOREWORD ; PREFACE ; List of Contributors ; Epidemiology and Prevalence of Down Syndrome ; 1. INTRODUCTION; 2. FACTORS AFFECTING THE RISK OF DOWN SYNDROME; 2.1. Maternal Age at Birth; 2.2. Altered Recombination Patterns Along Chromosome 21; 2.3. Maternal Grandmother Age; 2.4. Paternal Age; 2.5. Consanguinity; 2.6. Parity and Reproductive Function of the Mother; 2.7. Interval Between Pregnancies; 2.8. Previous Child with Down Syndrome; 2.9. Multiple Versus Singleton Pregnancies; 2.10. Environmental Factors |
2.10.1. Impact of Prenatal Diagnosis on the Prevalence of Down Syndrome and Rate of Pregnancy Termination2.10.2. Socioeconomic Status; 2.10.3. Exposure to Chemical Toxins, Drugs and Diseases; 3. PREVALENCE OF DOWN SYNDROME; 3.1. Prevalence in Africa; 3.2. Prevalence in Arab Worlds; 3.3. Prevalence in Asia; 3.4. Prevalence in Australia; 3.5. Prevalence in Europe; 3.6. Prevalence in North America (Fig. 4); 3.7. Prevalence in South America; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Genetics of Down Syndrome: An Update ; 1. INTRODUCTION: CHROMOSOMAL BASIS OF DOWN SYNDROME |
2. ETIOLOGY AND ORIGIN OF EXTRA CHROMOSOME 212.1. Nondisjunction Trisomy 21; 2.2. Robertsonian Translocation; 2.3. Mosaicism; 3. MOLECULAR GENETICS; 3.1. Genes Involved in Cognitive |
|
|
|
|
|
|
|
|
|
|
Impairment; 3.2. Genes Involved in Hematological Malignancies; 3.2.1. TAM: A Unique Hematological Finding in DS; 3.2.2. JAK2 Associated ALL in DS; 3.2.3. CBER1 Gene and Anthracycline- Related Cardiotoxicity in DS; 3.3. Genes Involved in Congenital Heart Disease (CHD); 3.4. Genes Involved in Immunological Dysfunctions; 4. THE BLESSING EFFECT OF EXTRA CHROMOSOME 21 ; 4.1. Protective Effects Against Solid Malignancy |
4.2. DS and Diabetic Retinopathy4.3. Anticancer Therapy; 4.4. Anti-Inflammatory Effect; 4.5. Vascular Anomalies; 4.6. Neuroprotective Effect!!!; 4.7. Lucky Mothers??; 5. GENE THERAPY IN DS: SILENCING THE EXTRA CHROMOSOME; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Neonates with Down Syndrome ; 1. INTRODUCTION; 2. DIAGNOSIS OF DOWN SYNDROME; 2.1. Antenatal Diagnosis; 2.1.1. Prenatal Screening ; 2.1.2. Invasive Prenatal Diagnosis; 2.2. Postnatal Diagnosis; 2.3. Informing the Parents; 3. GROWTH AND DEVELOPMENTAL CHARACTERISTICS OF NEONATES WITH DS |
4. MEDICAL PROBLEMS COMMON IN NEONATES WITH DS4.1. Congenital Heart Diseases; 4.2. Gastrointestinal Abnormalities; 4.3. Upper Airway Abnormalities; 4.4. Respiratory Abnormalities; 4.5. Endocrine Disorders; 4.6. Ophthalmic Disorders; 4.7. Hematologic Disorders; 4.8. Orthopedic Disorders; 4.9. Urinary Tract Disorders; 4.10. Dermatological Disorders; 4.11. Neurological Disorders; 4.12. Dental Disorders; 5. FEEDING NEONATE AND INFANT WITH DS; 5.1. Breastfeeding; 5.2. Bottle Feeding; 5.3. Weaning; 5.4. Feeding Problems for Neonates and Infants |
5.5. Nutritional Intervention in Neonates and Infants with DS |
|
|
|
|
|
| |